Hi-Tech Pharmacal Co., Inc. is a specialty manufacturer and marketer of prescription, over-the-counter and nutritional products. The Company develops, manufactures and markets products in three categories: generics, prescription brands and over-the-counter (OTC) brands. It produces a range of products for various disease states, including glaucoma, asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care and other conditions. The Company's generic products are primarily prescription items and include oral solutions and suspensions, topical creams and ointments as well as nasal sprays. It also specializes in the manufacture of products in its sterile facility capable of producing liquid ophthalmic, otic and inhalation products. In April 2014, Akorn Inc acquired Hi-Tech Pharmacal Co., Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:HITK
- CUSIP: 42840B10
- Web: N/A
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 15.76
- P/E Growth: N/A
Frequently Asked Questions for Hi-Tech Pharmacal (NASDAQ:HITK)
What is Hi-Tech Pharmacal's stock symbol?
Hi-Tech Pharmacal trades on the NASDAQ under the ticker symbol "HITK."
Who are some of Hi-Tech Pharmacal's key competitors?
Some companies that are related to Hi-Tech Pharmacal include Ampio Pharmaceuticals (AMPE), Pernix Therapeutics Holdings (PTX), Allergan plc (ACT), Auxilium Pharmaceuticals (AUXL), Avanir Pharmaceuticals (AVNR), Cadence Pharmaceuticals (CADX), Forest Laboratories (FRX), Optimer Pharmaceuticals (OPTR), Questcor Pharmaceuticals (QCOR), Salix Pharmaceuticals (SLXP), Santarus (SNTS), Shire Viropharma (VPHM) and Warner Chilcott Plc (WCRX).
How do I buy Hi-Tech Pharmacal stock?
Shares of Hi-Tech Pharmacal can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Hi-Tech Pharmacal stock cost?
One share of Hi-Tech Pharmacal stock can currently be purchased for approximately $43.49.
Consensus Ratings for Hi-Tech Pharmacal (NASDAQ:HITK) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Hi-Tech Pharmacal (NASDAQ:HITK)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Hi-Tech Pharmacal (NASDAQ:HITK)Earnings History by Quarter for Hi-Tech Pharmacal (NASDAQ:HITK)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/11/2014||Q314||$0.66||$0.70||$62.35 million||$59.90 million||View||N/A|
|12/10/2013||Q2||$0.47||$0.71||$57.97 million||$58.60 million||View||N/A|
|9/9/2013||Q1 2014||$0.44||$0.44||$57.78 million||$50.50 million||View||Listen|
|7/9/2013||Q4 2013||$0.63||$0.50||$66.33 million||$58.50 million||View||Listen|
|3/7/2013||Q3 2013||$0.71||$0.43||$60.45 million||$64.33 million||View||Listen|
|9/5/2012||Q113||$0.68||$0.44||$57.60 million||$52.00 million||View||N/A|
|12/9/2010||$0.56||$0.76||$42.47 million||$44.90 million||View||N/A|
Earnings Estimates for Hi-Tech Pharmacal (NASDAQ:HITK)
Current Year EPS Consensus Estimate: $2.38 EPS
Next Year EPS Consensus Estimate: $2.76 EPS
Dividend History for Hi-Tech Pharmacal (NASDAQ:HITK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Hi-Tech Pharmacal (NASDAQ:HITK)Insider Trades by Quarter for Hi-Tech Pharmacal (NASDAQ:HITK)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/13/2013||Gary April||Insider||Sell||6,873||$43.06||$295,951.38|| |
|10/10/2013||Reuben Seltzer||Chairman||Sell||11,250||$43.13||$485,212.50|| |
|10/8/2013||David Seltzer||CEO||Sell||23,000||$43.09||$991,070.00|| |
|10/4/2013||Martin Goldwyn||Director||Sell||1,500||$43.10||$64,650.00|| |
|10/3/2013||William J Peters||CFO||Sell||21,250||$43.11||$916,087.50|| |
|10/2/2013||Bruce W Simpson||Director||Sell||25,468||$43.15||$1,098,944.20|| |
|10/2/2013||Reuben Seltzer||Chairman||Sell||11,250||$43.13||$485,212.50|| |
|2/5/2013||William J Peters||CFO||Sell||4,639||$38.00||$176,282.00|| |
Headline Trends for Hi-Tech Pharmacal (NASDAQ:HITK)
Latest Headlines for Hi-Tech Pharmacal (NASDAQ:HITK)
Hi-Tech Pharmacal (HITK) Chart for Sunday, May, 28, 2017